Posted on
Alidad Mireskandari, Ph.D., Head of Product Development, Endocrine Business Unit at Interpace Diagnostics brings us a presentation, case studies and a Q&A.
Posted on
The TCC was honored to attend the Second Annual Thyroid Cancer Workshop at the North Shore University Hospital in Manhasset, NY 0n Saturday, June 9th. Read the story to find out more!
Posted on
The TCC will be at booth #628 at the AACE Annual Meeting this May 17-19.
Posted on
The annual Thyroid Cancer Survivor’s Workshop will be held on Saturday, June 9th in Manhasset, NY, and the TCC is extremely honored to have been invited to present to the attendees.
Posted on
We are pleased to announce that an article featuring the Thyroid Care Collaborative (TCC) has been published in the International Journal of Endocrine Oncology. The article describes all of the ways in which the TCC can be used a method of facilitating the multidisciplinary management of thyroid cancer.
Posted on
The TCC will be implementing the new AJCC staging rules into the pathology module this week.
Posted on
The TCC is happy to announce we are exhibiting at the Endocrinology and Endocrine Surgery Exhibition from December 7-9, 2017 at the Icahn School of Medicine at Mount Sinai in NY.
Posted on
The TCC is proud to be attending the 2oth annual THYCA (Thyroid Cancer Survivors’ Association) conference in Baltimore, MD October 6-8, 2017. We are also very excited to be able to help THYCA members get their records into the TCC for safekeeping, better coordination between their doctors, and research. THYCA is reaching out to its […]
Posted on
Thyroid cancer patients are often required to alter their dietary intake in preparation for either a radioiodine scan and/or treatment. Restricting the amount of iodine in the diet for a period of two weeks does not need to be overly challenging.
Posted on
A new drug, CUDC-907, that may be able to shrink thyroid tumors that have spread, is now in a phase II trial and being tested in advanced thyroid cancer patients. Currently there are no standard or effective treatment options for aggressive types of thyroid malignancies such as anaplastic and poorly differentiated thyroid cancer. The study […]
